This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at: https://awmsg.nhs.wales/.
awmsg logo



ketotifen (Ketofall®)


Reference No. 3930

Publication date:
16/06/2020


Appraisal information

ketotifen (Ketofall®) 0.1 mg in 0.4 ml solution eye drops


Company: Scope Ophthalmics Ltd
BNF category: Eye
NMG meeting date: 05/02/2020
AWMSG meeting date: 17/03/2020
   
   
Submission Type: Limited Submission
Status: Recommended with restrictions
Advice No: 0320
Ratification by Welsh Government: 15/06/2020

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government

AWMSG advice

Ketotifen (Ketofall®) is recommended as an option for restricted use within NHS Wales. Ketotifen (Ketofall®) should be restricted within its licensed indication for the symptomatic treatment of seasonal allergic conjunctivitis, to the subpopulation of patients who require a preservative-free treatment. Ketotifen (Ketofall®) is not recommended for use within NHS Wales outside of this subpopulation
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download